Intratech Medical - Israel

Intratech Medical is introducing Booster™ balloon catheter therapy to treat patients with acute myocardial infarction (AMI). This revolutionary device has the potential to reduce infarct size and improve clinical outcomes of these patients, while decreasing associated health care costs. Every year, 16 million people around the world suffer from a heart attack caused by a blockage in their coronary arteries, and approximately 6 million of these individuals have an AMI which requires immediate revascularization. Even after successful revascularization, up to 30% of patients may still experience an enlargement of the ischemic area around the infarcted heart muscle, increasing their risk of heart failure and mortality.

The Booster spiral balloon catheter is a patented device designed to  

Show more

reduce infarct-size and improve patient outcomes. It is inserted into the coronary sinus after revascularization and increases pressure in the heart venules and capillaries, without compromising the blood outflow. This elevated pressure improves oxygen delivery to the ischemic myocardium, reducing the infarct area and ultimately improving patient outcomes. Unlike other technologies, this catheter does not require an expensive console and can be used with standard catheterization laboratory equipment, making it simple and intuitive to use.

Intratech has promising pre-clinical results and will be launching its First-In-Human clinical study in Q3 2021. The company has also secured a major investment from a strategic corporation in